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Abstract
Background:  A sensitive, ubiquitously expressed tetracycline inducible system would be a
valuable tool in mouse transgenesis. However, this has been difficult to obtain due to position
effects observed at different chromosomal sites of transgene integration, which negatively affect
expression in many tissues. The aim of this study was to test the utility of a mammalian methylation-
free CpG island to drive ubiquitous expression of the sensitive doxycycline (Dox) inducible
rtTA2S-M2 Tet-transactivator in transgenic mice.
Results:  An 8 kb genomic fragment from the methylation-free CpG island of the human
hnRNPA2B1-CBX3 housekeeping gene locus was tested. In a number of transgenic mouse lines
obtained, rtTA2S-M2 expression was detected in many tissues examined. Characterisation of the
highest expressing rtTA2S-M2 transgenic mouse line demonstrated Dox-inducible GFP transgene
expression in many tissues. Using this line we also show highly sensitive quantitative induction with
low doses of Dox of an assayable plasma protein transgene under the control of a Tet Responsive
Element (TRE). The utility of this rtTA2S-M2 line for inducible expression in mouse embryos was
also demonstrated using a GATA-6 Tet-inducible transgene to show specific phenotypes in the
embryonic lung, as well as broader effects resulting from the inducible widespread overexpression
of the transgene.
Conclusion:  The ubiquitously expressing rtTA2S-M2 transgenic mouse line described here
provides a very useful tool for studying the effects of the widespread, inducible overexpression of
genes during embryonic development and in adult mice.
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Background
Controlling gene expression in a temporally and spatially
inducible manner is an important aspect of transgenic
approaches. A key development has been the application
of gene expression systems based on the tetracycline-
resistance (tet) operon of the Tn10 transposon of E. coli.
In the absence of tetracycline, the tet repressor (tetR) DNA
binding protein binds to a defined DNA operator
sequence (tetO) and suppresses transcription. Addition of
tetracycline (Tc) causes a conformational change in TetR
preventing it from binding to tetO [1]. In the tet transacti-
vator (tTA) system, tetR was fused to VP16, a strong tran-
scriptional activator, so that it now activates expression
upon binding to TetO in the absence of Tc [1]. It was fur-
ther improved by developing a reverse tet transactivator
(rtTA) which requires Tc for binding tetO for transactiva-
tion, thus eliminating long-term exposure to Tc [2]. Also,
doxycycline (Dox) was introduced as an inducer due to its
superior qualities of lower toxicity, longer half-life and
high bioavailabilty. Finally, the rtTA2S-M2 variant gener-
ated by mutagenesis constitutes a significant improve-
ment over the original rtTA since it is induced at a 10-fold
lower Dox concentration compared to rtTA, it shows no
background DNA binding and it is also more stable in
mammalian cells [3].
Application of the rtTA system in mice requires two trans-
genic lines: one line expressing the rtTA under an appro-
priate promoter and a second line carrying the target
transgene of interest linked to a Tet-responsive element
(TRE) containing tetO sequences. However, the efficiency
of the tet system in transgenic animals is often negatively
impacted by the chromosomal site of integration of the
transgenes. This becomes particularly important when
ubiquitous induction in several tissues is desirable.
Whereas chromosomal position effects can be partly alle-
viated by the use of gene domain regulatory elements such
as Locus Control Regions or insulators [4], these elements
are often tissue specific. By contrast, regulatory elements
associated with ubiquitously expressed housekeeping
genes are active in all tissues. For example, methylation-
free CpG islands associated with the 5' ends of housekeep-
ing genes are known to be localized in regions of active
chromatin [5]. Previous evidence from cell transfection
experiments has suggested that transgenes containing
CpG islands have the potential to protect from position
effects, even when integrated in heterochromatin. For
example, large fragments spanning CpG islands from the
ubiquitously expressed human TBP-PSMB1 and
hnRNPA2B1-CBX3 loci were able to protect from hetero-
chromatic silencing [6,7]. These regions are structurally
similar in that they contain divergently transcribed pro-
moters embedded within an extended CpG island. In the
hnRNPA2B1-CBX3 locus the two divergently expressed
genes code for heterogeneous ribonucleoprotein A2/B1
and for chromobox homolog 3 [8]. Assays in mammalian
cells showed that the hnRNPA2B1-CBX3 CpG island gave
rise to reproducible, stable and non-variegated expression
from the endogenous hnRNPA2B1 promoter, even when
integrated in centromeric heterochromatin [6]. Further-
more, the coupling of the hnRNPA2B1-CBX3 CpG island
to the CMV promoter gave substantial improvements in
the level and stability of expression, resulting in improved
production of recombinant proteins in CHO cells [9].
These observations suggest that methylation-free CpG
islands may harbor dominant chromatin remodeling
functions. In this report, we show that the hnRNPA2B1-
CBX3 CpG island is sufficient to generate an efficient,
ubiquitously expressed rtTA inducible system in trans-
genic mice.
Results and discussion
We used an ~8 kb DNA fragment encompassing the
human hnRNPA2/B1-CBX3 gene locus CpG island, which
includes the two divergently transcribed promoters (Fig.
1A). The rtTA2S-M2 variant was cloned under the control
of the hnRNPA2/B1 promoter as shown (Fig. 1A) and the
entire 8 kb fragment was purified and microinjected into
mouse fertilized eggs. A total of 10 founders transgenic for
the hnRNPA2B1-CBX3/rtTA2S-M2 construct were gener-
ated and seven transgenic lines were established through
transmission of the transgene. Transgenic founder 2 had
two integration sites, which separated upon breeding to
generate lines 2a and 2b. Integrity of the transgenes was
established by Southern blotting using the 8 kb DNA
microinjection fragment as probe (not shown). For the
majority of transgenic lines, we also determined transgene
copy numbers (Fig. 1B) and chromosomal integration
sites using FISH (summarized in Fig. 1C).
We next carried out Northern blot analysis to determine
the tissue distribution and relative expression levels of the
rtTA2S-M2 transgene in the different lines. Line 9 is clearly
the highest expressing line in all tissues tested, lines 2a
and 2b expressed weakly in some tissues, whereas lines 1,
4, 6 and 7 barely expressed (Fig. 2A). These data show that
transgene expression levels are not copy number depend-
ent and are prone to position effects. This was confirmed
by quantitative RT-PCR for lines 1, 2a, 2b, 4 and 9 in heart
and liver RNA. Plotting normalized levels of expression
against transgene copy numbers shows no direct correla-
tion between expression levels and copy numbers, for
example, the single copy line 9 expresses at much higher
levels than the multi copy line 2a (Additional file 1). The
chromosomal sites of integration of the transgenes cannot
readily account for these results. For example, line 4 carry-
ing 2 copies of the transgene in a euchromatic site does
not express, whereas single copy line 9, also integrated in
euchromatin, expresses at high levels. These observations
contrast with previous work in transfected cells showingBMC Developmental Biology 2007, 7:108 http://www.biomedcentral.com/1471-213X/7/108
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that a broader 16 kb genomic fragment spanning the
hnRNPA2B1-CBX3 locus expressed consistently even
when integrated in centromeric heterochromatin [6], or
that the 8 kb hnRNPA2B1-CBX3 fragment when linked to
a CMV promoter showed consistently detectable, though
variable, transgene expression for all integration events
[9]. Reasons that could account for these differences
include the requirement of additional elements for posi-
tion independent transgene expression which are lacking
from the 8 kb fragment we used [6], or that the use of anti-
biotic resistance in cell transfections introduces a bias for
open chromatin integration, particularly when using the
CMV promoter [9].
We next focused on the utility of the highly expressing line
9 as a tool for widespread inducible transgene expression
upon Dox treatment. We first obtained further evidence
that the rtTA2S-M2 transgene is indeed widely expressed
in this line. By employing RT-PCR, we detected expression
of the transgene in all tissues assayed (Fig. 2B), thus con-
firming the ubiquitous expression of the rtTA2S-M2 trans-
gene driven by the hnRNPA2B1-CBX3 CpG island. We
next generated three transgenic lines carrying a TRE-GFP
reporter construct and crossed them with line 9. Analysis
of GFP expression in the liver of adult mice treated with
Dox showed that TRE-GFP line 2 was induced more effi-
ciently than TRE-GFP lines 1 and 3 (data not shown).
Thus, TRE-GFP line 2 was used in all subsequent experi-
ments. Because of the high levels of autofluorescence
observed in the liver and other tissues (not shown), we
assayed induction of GFP expression in different tissues
by immunohistochemistry with an anti-GFP antibody
(Fig. 3). We observed clear induction of GFP expression in
the kidney, lung, heart, spleen and liver specifically upon
Dox treatment of double transgenic mice (Fig. 3). Thus,
taken together these results show that the rtTA2S-M2
transgene is expressed in the liver, heart, brain, ovary, kid-
ney, lung, spleen, muscle, thymus and blood (see below)
with Dox inducibility demonstrated in the liver, kidney,
heart, lung, spleen and blood (see below). To-date there
have been few other studies reporting the use of the
improved rtTA2S-M2 variant in transgenic mice, for exam-
ple, for the tissue specific inducible expression of genes in
the retinal ganglia cells or the brain [10,11]. Transgenic
mouse line 9 represents an important addition to the
transgenic tools that are available exploiting the superior
properties of the rtTA2S-M2 system.
Despite robust expression of the rtTA2S-M2 transgene in
the brain of line 9 (Fig. 2A and 2B), we were unable to
detect GFP induction in the brain (Fig. 3), even after treat-
ment with 2 mg/ml Dox for up to 18 days (not shown).
(A) Diagram of the 8 kb Hind III (H) genomic fragment showing the hnRNPA2B1 and CBX3 promoters and the CpG island that  spans them Figure 1
(A) Diagram of the 8 kb Hind III (H) genomic fragment showing the hnRNPA2B1 and CBX3 promoters and the CpG island that 
spans them. The Bgl II (B) site used for cloning the rtTA2S-M2SV40polyA cDNA is shown. The EcoRI (E) sites used for deter-
mining transgene copy numbers are also shown. (B) Southern blot of EcoRI digests of genomic DNA from the hnRNPA2B1-
rtTA2S-M2 transgenic mouse lines to determine transgene copy numbers. Probes used: an rtTA2S-M2 fragment detecting a 4.1 
kb band and, as control, a CAII probe detecting a 3.1 kb band from the endogenous carbonic anhydrase II locus. Lane 2a* 
shows a different exposure (n.t.: non transgenic). (C) Summary table of the transgene copy numbers for the different lines and 
of the chromosomal integration sites as determined by FISH (n.d.: not determined; n.centr.: near centromere; n.tel.: near tel-
omere).BMC Developmental Biology 2007, 7:108 http://www.biomedcentral.com/1471-213X/7/108
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This is most likely due to the well-known limited penetra-
tion of the blood-brain barrier by Dox. The study by
Michalon et al. [10] has suggested that induction in the
brain may require treating mice for longer periods with
higher doses of Dox. However, in the case of line 9 where
the rtTA2S-M2 transgene is expressed in many tissues, one
needs to keep in mind the potential side effects that pro-
longed treatment with high amounts of Dox may have in
tissues other than the brain [12].
In order to test the dose response of line 9 to Dox, we
crossed it with a transgenic mouse line expressing the
human phospholipid transfer protein (PLTP) under the
control of a Tet responsive element (TRE), which was cre-
ated for the purposes of another study (MM and RdC).
PLTP is a plasma protein with several key roles in lipopro-
tein metabolism and, potentially, atherogenesis [13,14].
We used a sensitive assay to measure PLTP activity in the
serum of double line 9/TRE-PLTP transgenic mice as a
means of quantifying induction with increasing Dox con-
centrations added to the drinking water. We found a 6- to
7-fold induction in PLTP activity for Dox concentrations
ranging from 0.25 to 2.0 mg/ml (Fig. 4). PLTP activity
appeared to decline with increasing Dox dosage (4.0 to
16.0 mg/ml, Fig. 4), however, these concentrations of Dox
are much higher than those normally used in mice for
induction. Thus, taken together, the data presented in Fig-
ure 4 establish a useful range of Dox concentrations for
inducing PLTP activity and, in addition, demonstrate the
superior sensitivity of induction in the serum of the
rtTA2S-M2 variant in transgenic mice with as little as 0.25
mg/ml of Dox.
In order to demonstrate the utility of line 9 for Dox induc-
ible expression in mouse embryos, we established a sensi-
tive genetic system based on a myc-tagged murine GATA-
6 transgene under the control of a TRE. GATA-6 is an
essential transcription factor with important functions in
endoderm differentiation (review, [15]). Importantly,
GATA-6 overexpression in transgenic embryos results in
branching defects in the lung, showing that lung develop-
ment is sensitive to GATA-6 dosage [16]. Microinjection
of the TRE-myc-GATA-6 fragment into fertilized eggs
resulted in 30 live born pups, of which 9 carried the trans-
(A) Northern blot analysis of rtTA2S-M2 transgene expression in different tissues in transgenic lines Figure 2
(A) Northern blot analysis of rtTA2S-M2 transgene expression in different tissues in transgenic lines. Probe used was the 
rtTA2S-M2 fragment. Lower panels: rRNA loading control visualized by ethidium bromide staining. (B) RT-PCR of rtTA2S-M2 
transgene expression in different tissues in transgenic line 9 (nt: non transgenic, tg: transgenic). Expression of the endogenous 
HPRT gene was used as control.BMC Developmental Biology 2007, 7:108 http://www.biomedcentral.com/1471-213X/7/108
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gene as deduced by Southern blot analysis (not shown).
Three lines were chosen for further analysis based on the
intensity of the signal on Southern blots. All heterozygous
and homozygous TRE-myc-GATA-6 mice were viable and
showed no defects. Timed pregnancies were set up
between HNRPA2B1-rtTA2S-M2 homozygous mice and
TRE-myc-GATA-6 heterozygous mice. Dox was given to
pregnant dams for one day before isolating embryos (see
Methods). Since it has been previously shown that overex-
pression of the myc-GATA-6 transgene results in defects in
the differentiation of the airway epithelium of the lung
[16], we examined the lungs of double transgenic pups
that were treated with Dox. We found striking similarities
with the published lung phenotype, in that the airways
appear dilated with some bleeding also evident (Fig. 5A
and 5B). The lung phenotype was observed in all three
independent TRE-myc-GATA-6 lines and appeared only in
double transgenics treated with Dox. There was no obvi-
Immunohistochemistry on sections from the heart, lung, spleen, kidney, liver and brain of hnRNPA2B1-rtTA2S-M2/TRE-GFP  double transgenic mice (top panels) and of control TRE-GFP mice (lower panels), all treated with 2 mg/ml Dox for 3–4 days  and stained with an anti-GFP antibody (scale bars: 10 µm) Figure 3
Immunohistochemistry on sections from the heart, lung, spleen, kidney, liver and brain of hnRNPA2B1-rtTA2S-M2/TRE-GFP 
double transgenic mice (top panels) and of control TRE-GFP mice (lower panels), all treated with 2 mg/ml Dox for 3–4 days 
and stained with an anti-GFP antibody (scale bars: 10 µm).BMC Developmental Biology 2007, 7:108 http://www.biomedcentral.com/1471-213X/7/108
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ous lung phenotype in double transgenics not treated
with Dox (not shown). Furthermore, Dox treatment of
pregnant dams for only one day also resulted in gross
morphology defects in that the embryos showed loosen-
ing of the skin and signs of oedema (Fig. 5C and 5D).
These observations could be due to interference of normal
GATA factor functions in the skin as a result of induced
myc-GATA-6 overexpression [17,18]. Induction of the
transgene for more than one day resulted in a general
growth arrest and death in utero. Thus, these observations
reveal defects that are specific for the induction of the
myc-GATA-6 transgene and demonstrate the utility of
hnRNPA2B1-rtTA2S-M2 line 9 in studying the effects of
the widespread inducible overexpression of specific fac-
tors in embryonic development. Alternatively, this system
could be used for timed rescue experiments of mice that
have essential genes knocked out.
Conclusion
In conclusion, we showed that the methylation free CpG
island of the human housekeeping hnRNPA2B1-CBX3
gene locus is capable of driving expression of a linked
rtTA2S-M2 transgene in mice in all tissues that were exam-
ined. Transgene expression was not found to be copy
number related, suggesting that the CpG island does not
completely escape chromosomal position effects in vivo.
However, in line 9 where the transgene is most active, it is
expressed in all tissues tested. Furthermore, using this sys-
tem we demonstrated that the highly expressing line 9 is a
very useful tool for the inducible, sensitive expression of
transgenes in a variety of tissues in response to Dox treat-
ment. Importantly, the inducible transgenic system
reported here can be used to examine the effects of induc-
ing widespread overexpression of transcription factors
during mouse development.
Methods
DNA constructs
An 8 kb genomic fragment spanning the CpG island of the
HNRPA2B1-CBX3 locus was used to express the rtTA
derivative rtTA2S-M2. The latter was obtained as an EcoRI-
HindIII fragment, including the SV40 polyA sequence,
from plasmid pUHrT62-1 [3] and was blunt-end cloned
into a Bgl II site in the first exon of the HNRPA2B1 gene.
The cDNAs for GFP and human PLTP [19] and murine N-
terminally myc-tagged GATA-6 [20] were cloned under
the control of a TetO-CMV promoter in plasmids pTRE
(GFP and PLTP) or pTRE-Tight (GATA-6) (Clontech).
Transgenic mice
HNRPA2B1/rtTA2S-M2 was released from vector
sequences as an 8 kb HindIII fragment (Fig. 1A). TRE-
GFP-SV40polyA and TRE-hPLTP-SV40polyA were released
from vector sequences as XhoI/PvuII fragments. TRE-myc
tag-GATA-6-SV40polyA was released as an XhoI fragment.
All fragments were purified by salt gradient centrifugation,
as previously described [21], microinjected at approxi-
mately 0.5 ng/µL into the pronucleus of fertilized eggs of
FVB/N mice and transplanted into the oviducts of pseudo-
pregnant B10xCBA mice [22]. Transgenic founders were
identified by Southern blotting using the rtTA2S-M2, GFP,
hPLTP and GATA-6 fragments as probes. The integrity of
the HNRPA2B1/rtTA2S-M2 transgene was checked by
hybridization using the entire HNRPA2B1/rtTA2S-M2
construct as probe. Transgene copy numbers for the
HNRPA2B1/rtTA2S-M2 lines were determined from the
intensity of fragments using an EcoRI/BamHI rtTA2S-M2
probe, together with a 0.9-kb Pvu I probe detecting the
endogenous mouse carbonic anhydrase II (CA-II) gene.
PhosphorImager analysis was performed using Image-
Quant software (Molecular Dynamics, Sunnyvale, CA).
All animal experiments described in this work conformed
to national and institutional guidelines.
DNA fluorescence in situ hybridization analysis
FISH was carried out to determine chromosomal sites of
transgene integration, as previously described [23,24].
The specific probe used was the biotin-labeled
HNRPA2B1/rtTA2SM2 injection fragment.
Doxycycline induction
Mice (2–4 months old) were kept on drinking water con-
taining 5% sucrose for three days, followed by drinking
water containing 2 mg/ml doxycycline hydrochloride
(Sigma) plus 5% sucrose for 3–4 days. Doxycycline-con-
taining drinking water was protected from light. Negative
control mice were kept on drinking water containing 5%
sucrose for the same time period. The drinking water was
PLTP activity in serum following administration of increasing  amounts of Dox in the drinking water, as indicated Figure 4
PLTP activity in serum following administration of increasing 
amounts of Dox in the drinking water, as indicated. PLTP 
activity is expressed as percentage of human reference 
plasma.BMC Developmental Biology 2007, 7:108 http://www.biomedcentral.com/1471-213X/7/108
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replaced every 2–3 days. Doxycycline induction of the
myc-GATA-6 transgene expression in embryos: after the
identification of a vaginal plug in the morning, dams
bearing single and double (HNRPA2B1/rtTA2S-M2 and
myc-GATA-6) transgenic pups were given doxycycline in
the drinking water (2 mg/ml supplemented with 5%
sucrose) for 1–4 days, after which embryos were isolated
at different gestational ages and processed for further
analysis.
Northern blot analysis
RNA was isolated using the Trizol reagent and according
to the manufacturer's instructions (Invitrogen). Northern
blot analysis was carried out with 5 µg of total RNA as pre-
viously described [25]. The rtTA2S-M2 fragment was used
as probe for hybridization.
RT-PCR and Quantitative RT-PCR
RNA was treated with RQ1 RNase-Free DNase I (Promega)
for 30 minutes at 37°C according to the manufacturer's
instructions. DNase-treated RNA samples were reverse
transcribed with Superscript (Invitrogen) using oligo dT.
Control reactions without reverse transcriptase (RT) were
also performed. Real-time PCR reactions were performed
in triplicate with a Chromo 4, MJ Research RealTime PCR
Cycler, as previously described [26]. Normalization for
the amount of template was done using primers specific
for exon 8 of the mouse HPRT gene. Primer sequences for
rtTA2S-M2 and HPRT are available upon request. Data
were analyzed using the Chromo 4, MJ Research RealTime
PCR software and statistical analysis was done using the
comparative CT method for the relative quantitation of
results [27]. Post amplification denaturation curves
showed that the primer pairs generated single products.
(A-B) Whole mount view of the lungs of the double transgenic and the control littermate showing the enlargement of the air- spaces, which are highlighted in B (top is the non-Tg and lower is the Tg lung) Figure 5
(A-B) Whole mount view of the lungs of the double transgenic and the control littermate showing the enlargement of the air-
spaces, which are highlighted in B (top is the non-Tg and lower is the Tg lung). (C) Lateral views of a double transgenic 
hnRNPA2B1-rtTA2S-M2 line 9/TRE-myc-GATA-6 (Tg) and a control litter mate (non-Tg) at gestational age 12.5 dpc 24 hours 
after start of induction with Dox. The arrow indicates the clearly visible oedema after induction of the GATA-6 transgene. (D) 
Ventral (top) and dorsal (bottom) views of the double transgenic hnRNPA2B1-rtTA2S-M2 line 9/TRE-myc-GATA-6 to show 
the clear indication of oedema (arrows).BMC Developmental Biology 2007, 7:108 http://www.biomedcentral.com/1471-213X/7/108
Page 8 of 9
(page number not for citation purposes)
PLTP activity assay
Blood samples were collected from the orbital plexus of
mice before the sucrose run-in period, after three days of
plain sucrose administration and after three days of doxy-
cycline administration. Blood was centrifuged at 2800
rpm for 15 minutes at 4°C and plasma samples stored at
-80°C. PLTP activity was measured using a phospholipid
vesicle-HDL system [28]. Radiolabelled phospholipid ves-
icles were prepared by mixing egg phosphatidylcholine
(Sigma) with [14C]dipalmitoylphosphatidylcholine
(Amersham) and butylated hydroxytoluene (Sigma), fol-
lowed by drying under N2 and sonification. EDTA-plasma
samples (5 µl of plasma diluted 1:150) and phospholipid
vesicles were incubated in the presence of isolated human
HDL for 45 minutes at 37°C. After incubation, the vesi-
cles were precipitated and the radioactivity transferred to
HDL was counted in the supernatant by liquid scintilla-
tion. PLTP activity was expressed as a percentage of
human reference plasma (100% is equivalent to 14 µmol/
ml/h).
Perfusion of mice
Mice were sacrificed using an overdose of isoflurane (1-
chloro-2,2,2-trifluoroethyl-difluoromethyl-ether). Subse-
quently, in situ perfusion fixation was performed by flush-
ing 20 ml PBS through a cardiac puncture followed by 20
ml 4% (v/v) paraformaldehyde in PBS.
Immunohistochemistry
Immunohistochemistry was performed on cryosections as
previously described [29], with the following modifica-
tions: endogenous peroxidase activity was inhibited by a
30 min incubation in 1% H2O2 in methanol. A rabbit pol-
yclonal anti-GFP antibody (Abcam ab290) was used in a
dilution of 1:200. Rabbit IgG (Santa Cruz) was used as a
negative control in dilution of 1:500. Anti rabbit HRP-
conjugated IgG was used as secondary antibody at a 1:500
dilution. Antigen-antibody complexes were visualized by
incubation in substrate solution, containing hydrogen
peroxide and 3,3'-diaminobenzidine HCl (DAB substrate
kit for peroxidase, Vector Laboratories). Photographs were
recorded with a digital camera (Olympus DP 50) on a
light Olympus Microscope (BX 40 with U-DO Dual
View).
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